Litcius/Paper detail

The antibody–drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial

Dan‐Yun Ruan, Hao‐Xiang Wu, Suxia Luo, Wenwen Huang, Xinjun Liang, Zuo-Xing Niu, Qi Dang, Hongli Li, Zhanyu Pan, Hongxia Lu, Yanqiao Zhang, Xingya Li, Xiuying Xiao, Shirong Cai, Yugang Dong, Jian Zhang, Li Zhou, Haitao Lan, Xin Wang, Ying Zhou, Rui Li, Heli Liu, Ping-Sheng Xu, Aili Suo, Ruinuo Jia, Yong-Qiang Li, Xiaodong Peng, Si-Chen Wang, Aihong Yu, Jie Xie, Miao‐Zhen Qiu, Rui‐Hua Xu

2025Nature Medicine17 citationsDOI

Topics & Concepts

Gastroesophageal JunctionMedicineCancerAntibody-drug conjugateConjugateDrugAdeptAntibodyInternal medicinePharmacologyImmunologyAdenocarcinomaMonoclonal antibodyProdrugMathematical analysisMathematicsGastric Cancer Management and OutcomesGastrointestinal Tumor Research and TreatmentHER2/EGFR in Cancer Research
The antibody–drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial | Litcius